Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 5/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | HSD17B2 | P37059 | 5/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.43 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TSPO | P30536 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1573360 | 0.91 | MEN1 (0.46) | TACR1MEN1KMT2AHSD17B2POLB | |
| SCHEMBL1573013 | 0.77 | TACR1 (0.49) | TACR1MEN1KMT2AHSD17B2POLB | |
| SCHEMBL15831230 | 0.76 | MEN1 (0.62) | MEN1KMT2AHSD17B2POLBHPGD | |
| SCHEMBL1572940 | 0.76 | LMNA (0.51) | TACR1MEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL9112410 | 0.74 | TACR1 (0.70) | TACR1MEN1KMT2AHPGDALDH1A1 | |
| SCHEMBL10702424 | 0.73 | MAPT (0.55) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL6417242 | 0.71 | HSD17B2 (0.63) | MEN1KMT2AHSD17B2POLBHPGD | |
| SCHEMBL27416257 | 0.71 | MEN1 (0.49) | TACR1MEN1KMT2AHSD17B2POLB | |
| SCHEMBL3996160 | 0.70 | HSD17B2 (0.61) | MEN1KMT2AHSD17B2POLBHPGD | |
| SCHEMBL27535141 | 0.70 | MEN1 (0.48) | TACR1MEN1KMT2AHSD17B2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8044067-B2 | Isoquinolines as IGF-1R inhibitors | ANALYTECON S.A. (CH) | 2011-10-25 | — | — | US | disclosed |
| EP-1931636-B1 | ISOQUINOLINES AS IGF-1R INHIBITORS | ANALYTECON SA (CH) | 2011-04-13 | — | — | EP | disclosed |
| US-20090099229-A1 | Isoquinolines as IGF-1R Inhibitors | ANALYTECON S.A (CH) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099229-A1 | Isoquinolines as IGF-1R Inhibitors | IGF1R, IGFBP1, IGF2BP1 | TACR1 1191/4885MEN1 893/4885KMT2A 1238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.